Results 181 to 190 of about 5,494 (193)

Thinking beyond the Aducanumab Controversy

Annals of Neurology, 2021
openaire   +2 more sources

Accelerated Approval of Aducanumab: Where Do We Stand Now?

Annals of Pharmacotherapy, 2022
Hedva Barenholtz Levy
exaly  

Aducanumab: Boon or bust?

The Brown University Psychopharmacology Update, 2021
openaire   +1 more source

Aducanumab: Appropriate Use Recommendations

Alzheimer's and Dementia, 2022
Jeffrey L. Cummings
exaly  

Potential Eligibility for Aducanumab Therapy in an Irish Specialist Cognitive Service—Utilising Cerebrospinal Fluid Biomarkers and Appropriate Use Criteria

International Journal of Geriatric Psychiatry, 2022
Zara Togher, Sean Kennelly, Helena Dolphin   +2 more
exaly  

Aducanumab/donepezil/memantine

Reactions Weekly, 2023
openaire   +1 more source

Reply to “Thinking beyond Aducanumab Controversy”

Annals of Neurology, 2021
openaire   +2 more sources

AGS Perspective: AGS in Action, Aducanumab

Journal of Gerontological Nursing, 2021
openaire   +2 more sources

Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies

2022
exaly  

Results From the Long-Term Extension of PRIME: A Randomized Phase 1b Trial of Aducanumab

Alzheimer's and Dementia
Samantha Budd Haeberlein, John O'Gorman, Philipp von Rosenstiel   +2 more
exaly